Mizuho lowered the firm’s price target on Dentsply Sirona (XRAY) to $16 from $18 and keeps a Neutral rating on the shares. The firm believes many companies in the dental sector “may post less-than-stellar growth” in Q1. The recent American Dental Association Q1 survey results further reinforce a cautious view, so Mizuho trimmed Q1 estimates for broad dental manufacturers, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona downgraded to Equal Weight at Morgan Stanley
- Dentsply Sirona downgraded to Equal Weight from Overweight at Morgan Stanley
- Dentsply Sirona price target lowered to $16 from $19 at BofA
- Dentsply Sirona files automatic mixed securities shelf
- Dentsply Sirona appoints David Ferguson as SVP, global business unit leader